Hypoglycemia is the limiting factor in the management of diabetes.
about
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal controlDifferential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistanceModular closed-loop control of diabetesMultilevel model of type 1 diabetes mellitus patients for model-based glucose controllers.Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyAssociation of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetesModels of glucagon secretion, their application to the analysis of the defects in glucagon counterregulation and potential extension to approximate glucagon action.Pancreatic network control of glucagon secretion and counterregulation.System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.Linear quadratic gaussian-based closed-loop control of type 1 diabetes.Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated ratsIncreased density of glucagon receptors in liver from endurance-trained rats.Impact of symptomatic hypoglycemia on medication adherence, patient satisfaction with treatment, and glycemic control in patients with type 2 diabetes.Comparison of Antidiabetic Regimens in Patients with Type 2 Diabetes Uncontrolled by Combination Therapy of Sulfonylurea and Metformin: Results of the MOHAS Disease Registry in Korea.Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspensionA prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design.Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences.Influence of erythropoietin on cognitive performance during experimental hypoglycemia in patients with type 1 diabetes mellitus: a randomized cross-over trialAn overview of insulin glargine.Addressing dosing frequency in diabetes: a simple approach to improving adherence to therapy and clinical outcomes.A review of basal insulins.Defective glucagon secretion during hypoglycemia after intrahepatic but not nonhepatic islet autotransplantation.Continuous glucose monitors: use of waveform versus glycemic values in the improvements of glucose control, quality of life, and fear of hypoglycemiaInsulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.Insulin glargine in the treatment of type 1 and type 2 diabetes.Unlocking the opportunity of tight glycaemic control. Promise ahead: the role of inhaled insulin in clinical practice.Safety and side effects of the insulin analogues.Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.Subconjunctivally Implanted Hydrogels for Sustained Insulin Release to Reduce Retinal Cell Apoptosis in Diabetic RatsAcute bout of exercise induced prolonged muscle glucose transporter-4 translocation and delayed counter-regulatory hormone response in type 1 diabetes'Dead in bed syndrome--a hypothesis'.Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.Insulin aspart: a review.Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemiaType 1 diabetes: exercise and hypoglycemia.Microscale enzymatic optical biosensors using mass transport limiting nanofilms. 1. Fabrication and characterization using glucose as a model analyte.A novel method for assessing insulin dose adjustments by patients with diabetes.Islet transplantation in type 1 diabetes: hype, hope and reality - a clinician's perspective.
P2860
Q26853250-E245C61E-7F49-4C66-ABE1-185A0BA5579EQ28743462-E514EFCC-81FF-4456-9D91-8C4E7337C05EQ30370427-719BB3E1-8F06-484E-B630-F006E92D85F2Q30415524-194AD5B5-96C2-469C-841F-3FAFF9B262DEQ30424699-6607DC57-E707-4BA2-8395-A969968CA74FQ30427914-BF33FF89-EB3B-4BED-AC7F-551AC330ABDEQ30429992-574D9045-DE90-4262-81DA-C360B979279BQ30432736-9AA34644-176D-45BD-998D-558AB8FED9C6Q30437499-103488D6-CCC3-40F6-A7D6-2759F934B330Q30438608-5B6A2433-EDE0-4BA9-B57B-68938341A810Q30438739-FA812095-957A-48A6-8682-25E95C3C184BQ31713092-936612AA-E9C8-40A1-8CBF-FE2C830A1872Q33573537-6489EDA6-8F6C-40FA-8BE1-1B76A7A23C2BQ33849111-7FC13F2B-1F24-4427-8E06-56207292D603Q34302184-B2B250A1-0F5A-4ADD-B9C3-014080917DCCQ34315270-A684AC00-9D7D-4171-9C2D-0F521B0F87A1Q34627382-9CFF0881-7C65-42E1-86CD-26F22037EC75Q34663582-3C0B1A94-4290-4CD4-8DAD-0B8D318B88F4Q34906412-567890AE-5D55-4383-8AFE-71C9A9B2F755Q35175088-D0450C3C-8050-4E2F-AC17-BFECE356A81AQ35591062-FC10F779-0BF4-4071-926D-410EFC47EF52Q35632635-5CB33483-31DA-4135-8D11-69040AB59445Q35682809-5793D024-A2AE-416E-84A4-1256BDB88C14Q35807316-99EA9A3B-F023-4590-A243-C1EB332E293AQ36012923-69D15047-410F-4FA4-9D21-8A1072015425Q36245835-E2B65560-F8A9-4BEF-83A7-47BA6D6236E5Q36349754-8B1BC49C-C17F-4B0D-91E2-9C52C1BD7CAAQ36361469-A9940204-7B7B-431A-9CCE-E6E1168E8F42Q36366176-BBEF3358-71D2-4E75-8741-F4584CAF01E8Q36380233-1242B832-6995-4E75-9DCC-3B4D7738C39EQ36389577-27552112-0D73-42BF-B654-B0DE42CD7D15Q36458550-01490FB5-5EAD-4D93-9D68-C2E2F0E316D3Q36574084-54C7253F-73F7-49C7-894C-F3D16CA0E1E5Q36609772-5436CF4D-9AE5-4CE6-8444-E6DF0614F97FQ36712865-F98E0648-B162-4DE7-A53D-7FD6592F7960Q36735585-297579D0-CBD8-41B9-B68C-8E8BF5A91689Q36825651-8F6F9395-998F-43D3-B70B-4724738D1BADQ36842915-8F4CA610-7ED1-41CE-8B48-8681A4A95FC4Q37403945-DAEFE207-745A-4120-BBE1-2FA5C8737FE5Q38152410-F4BBFF48-4532-4CDE-B6B8-C4BB4C9CB14E
P2860
Hypoglycemia is the limiting factor in the management of diabetes.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Hypoglycemia is the limiting factor in the management of diabetes.
@en
type
label
Hypoglycemia is the limiting factor in the management of diabetes.
@en
prefLabel
Hypoglycemia is the limiting factor in the management of diabetes.
@en
P2860
P1476
Hypoglycemia is the limiting factor in the management of diabetes.
@en
P2093
P2860
P356
10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO;2-B
P577
1999-01-01T00:00:00Z